|
|
|
UroToday is excited to bring you written conference highlights, written by uro-oncologists from the 2020 AUA Live Virtual Experience, June 2020
|
|
|
|
|
|
|
The American Urological Association Virtual Meeting |
|
|
|
| AUA Guidelines Case-Based Panel Discussion: Bladder Cancer (Non-Muscle and Muscle Invasive)
|
Moderator: Sam Chang, MD
Panelists: Elizabeth Plimack, Sima Porten, MD, MPH, Joshua Meeks, MD, Ph.D., Ronald Chen, MD, MPH
|
| At the AUA 2020 virtual annual meeting, Sam Chang moderated a case-based panel discussion on both non-muscle and muscle-invasive bladder cancer. Areas of focus for this discussion included (i) CIS, (ii) T1 bladder cancer, (iii) multimodality therapy for invasive disease, and (iv) advances for metastatic bladder cancer.
|
|
|
|
|
|
|
|
|
AUA Guidelines Case-Based Panel Discussion: Bladder Cancer (Non-muscle and Muscle Invasive)
|
Sima Porten, MD, MPH and Josh Meeks, MD, Ph.D.
Ashish Kamat is joined by Sima Porten, and Joshua Meeks, panelist in the AUA Guidelines Case-Based Panel Discussion on Non-muscle and Muscle Invasive Bladder Cancer. They provide their perspectives on bladder cancer patient guidelines-based management and the specific management of bladder cancer patients.
|
|
|
|
|
|
|
|
|
|
| What to Do During BCG Shortage for High-Risk NMIBC Patients?
|
Seth P. Lerner, MD, FACS, Steve Boorjian, MD, Ashish Kamat, MD, MBBS,
James McKiernan, MD, Chad Ritch, MD, MBA
|
| In a plenary session at the AUA Virtual Annual Meeting, Dr. Seth Lerner moderated a session designed to answer the question of “What to do During BCG Shortage for High-Risk NMIBC Patients?.” Panelists Drs. Steve Boorjian, Ashish Kamat, James McKiernan, and Chad Ritch discussed a number of treatment options.
|
|
|
|
|
|
| Surgical Techniques: Tips & Tricks: Oncology: Bladder Cancer Blue Light Cystoscopy
|
| Anne Schuckman, MD
|
| Anne Schuckman discussed blue light cystoscopy for bladder cancer and several of her tips and tricks. Dr. Schuckman notes that there are over 75,000 new bladder cancer diagnoses per year, leading to more than 15,000 deaths. The prevalence of bladder cancer is >550,000 cases, making it the highest per capita treatment cost due to recurrent disease and multiple recurrences.
|
|
|
|
|
|
| John K. Lattimer Lecture: The Urinary Microbiome Impacts Urologic Disease
|
| J. Curtis Nickel MD, FRCSC
|
| The John K. Lattimer Lecture at the 2020 American Urologic Association virtual annual meeting was provided by Dr. J. Curtis Nickel, discussing the impact of the urinary microbiome on urologic disease.
|
|
|
|
|
|
|
|
|
|
|
| Pain Management in Urologic Surgery
|
| Angela Smith, MD, MS
|
| Angela Smith moderated a session examining “Pain Management in Urologic Surgery”. Along with panelists Drs. Jay Simhan, Nicole Miller, and Ben Davies, Dr. Smith highlights issues relating to opioid use both widely in the community and specifically among surgical patients, as well as potential treatment approaches to decrease their utilization.
|
|
|
|
|
|
| Diagnostic Performance of MCM5 in the Diagnosis of Recurrent Bladder Cancer: Results from a Large Prospective, Blinded, Multicenter European Study
|
| Joan Palou, MD
|
| At the AUA 2020 virtual annual meeting, Joan Palou and colleagues presented results of their study determining the diagnostic performance of ADXBLADDER in the detection of non-muscle invasive bladder cancer recurrence.
|
|
|
|
|
|
| BCG vs Chemohyperthermia with Mitomycin C for High-Risk Non-Muscle Invasive Bladder Carcinoma: Preliminary Results of HIVEC-HR Randomized Clinical Trial
|
| Felix Guerrero-Ramos, MD, Ph.D., FEBU
|
| At the 2020 AUA virtual annual meeting, Dr. Guerrero-Ramos and colleagues presented preliminary results of this trial since randomization had been completed. This study was an open pilot randomized clinical trial 1:1 including patients with high-risk non-muscle-invasive bladder cancer according to EAU Guidelines. Patients with CIS, intolerance or contraindication for receiving BCG or mitomycin C were excluded.
|
|
|
|
|
|
|
|
|
|
|
|
